SCHEMBL4714979

SCHEMBL4714979

CCCOC(=O)C(O)CCC

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 2/20 0.39
HDAC2 Q92769 2/20 0.39
HDAC3 O15379 1/20 0.39
HDAC4 P56524 1/20 0.39
HDAC7 Q8WUI4 1/20 0.39
HDAC10 Q969S8 1/20 0.39
HDAC11 Q96DB2 1/20 0.39
HDAC8 Q9BY41 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
HDAC9 Q9UKV0 1/20 0.39
HDAC5 Q9UQL6 1/20 0.39
HCAR2 Q8TDS4 1/20 0.39
ALDH1A1 P00352 2/20 0.38
CHRM1 P11229 2/20 0.37
TDP1 Q9NUW8 2/20 0.37
AKR1A1 P14550 1/20 0.37
CHRM3 P20309 1/20 0.37
HTR2A P28223 1/20 0.37
HTR2C P28335 1/20 0.37
ADRA1A P35348 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30775582 0.86 ALDH1A1 (0.52) HCAR2ALDH1A1TDP1TSHRGPR84
SCHEMBL4717732 0.86 GPR84 (0.47) ALDH1A1TDP1TSHRCYP3A4GPR84
SCHEMBL28144438 0.86 HCAR2 (0.36) HDAC1HDAC2HDAC3HDAC4HDAC7
SCHEMBL821952 0.86 ACHE (0.41) HDAC1HDAC2HDAC3HDAC4HDAC7
SCHEMBL3017297 0.86 ALDH1A1 (0.52) HCAR2ALDH1A1TDP1TSHRGPR84
SCHEMBL6004299 0.85 NAAA (0.55) HCAR2ALDH1A1TSHRCYP3A4NPSR1
SCHEMBL15005638 0.85 TSHR (0.37) HDAC1HDAC2HDAC3HDAC4HDAC7
SCHEMBL28216157 0.85 HSD17B10 (0.35) HDAC1HDAC2HDAC3HDAC4HDAC7
SCHEMBL4713218 0.85 GPR84 (0.55) GPR84NAAAFFAR1
SCHEMBL820658 0.83 ALDH1A1 (0.43) HDAC1HDAC2ALDH1A1CHRM1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2006119283-A2 ANTI-ODOR COMPOSITIONS AND THERAPEUTIC USE YU RUEY J (US) 2006-11-09 WO claimed
US-20060251597-A1 ANTI-ODOR COMPOSITIONS AND THERAPEUTIC USE YU RUEY J 2006-11-09 US claimed
WO-2025132660-A1 METHOD FOR TREATING HUMAN PERSPIRATION, AND ASSOCIATED COMPOSITION L'OREAL (FR) 2025-06-26 WO disclosed
US-20250009621-A1 ANHYDROUS HAIR TREATMENT COMPOSITION COMPRISING ALPHA HYDROXY ACID ESTER L'OREAL (FR) 2025-01-09 US disclosed
WO-2025006991-A1 ANHYDROUS HAIR TREATMENT COMPOSITION COMPRISING ALPHA HYDROXY ACID ESTER L'OREAL (FR) 2025-01-02 WO disclosed
EP-1874407-B1 SUBSTANCES AND PHARMACEUTICAL COMPOSITIONS FOR THE INHIBITION OF GLYOXALASES AND THEIR USE AS ANTI-FUNGAL AGENTS BIOMAC PRIVATINSTITUT FÜR MEDIZINISCHE UND ZAHNMEDIZINISCHE FORSCHUNG ENTWICKLUNG UND DIAGNOSTIK GMB (DE) 2015-09-09 EP disclosed
EP-1877141-B1 SUBSTANCES AND PHARMACEUTICAL COMPOSITIONS FOR THE INHIBITION OF GLYOXALASES AND THEIR USE AGAINST BACTERIA BIOMAC PRIVATINSTITUT FUER MEDIZINISCHE UND ZAHNMEDIZINISCHE FORSCHUNG ENTWICKLUNG UND DIAGNOSTIK GM (DE) 2013-06-12 EP disclosed
CN-101482698-B Resist composition DAICEL CHEM 2012-07-04 CN disclosed
CN-101220229-B Dye dispersion liquid DAICEL CHEM 2012-05-23 CN disclosed
CN-101482698-A Resist composition DAICEL CHEM (JP) 2009-07-15 CN disclosed
CN-101220229-A Dye dispersion liquid DAICEL CHEM (JP) 2008-07-16 CN disclosed
WO-2006108681-A2 SUBSTANCES AND PHARMACEUTICAL COMPOSITIONS FOR THE INHIBITION OF GLYOXALASES AND THEIR USE AGAINST BACTERIA BIOMAC PRIVATINSTITUT FÜR MEDIZINISCHE UND ZAHNMEDIZINISCHE FORSCHUNG, ENTWICKLUNG UND DIAGNOSTIK GMBH (DE) 2006-10-19 WO disclosed
WO-2006108679-A2 SUBSTANCES AND PHARMACEUTICAL COMPOSITIONS FOR THE INHIBITION OF GLYOXALASES AND THEIR USE TO COMBAT CANCER BIOMAC PRIVATINSTITUT FÜR MEDIZINISCHE UND ZAHNMEDIZINISCHE FORSCHUNG, ENTWICKLUNG UND DIAGNOSTIK GMBH (DE) 2006-10-19 WO disclosed
WO-2006108682-A2 SUBSTANCES AND PHARMACEUTICAL COMPOSITIONS FOR THE INHIBITION OF GLYOXALASES AND THEIR USE AS ANTI-FUNGAL AGENTS BIOMAC PRIVATINSTITUT FÜR MEDIZINISCHE UND ZAHNMEDIZINISCHE FORSCHUNG, ENTWICKLUNG UND DIAGNOSTIK GMBH (DE) 2006-10-19 WO disclosed
WO-2006108680-A2 SUBSTANCES AND PHARMACEUTICAL COMPOSITIONS FOR THE INHIBITION OF GLYOXALASES AND THEIR USE AGAINST PROTOZOA AND HELMINTHES BIOMAC PRIVATINSTITUT FÜR MEDIZINISCHE UND ZAHNMEDIZINISCHE FORSCHUNG, ENTWICKLUNG UND DIAGNOSTIK GMBH (DE) 2006-10-19 WO disclosed
CN-1813221-A Resist composition SHOWA DENKO KK (JP) 2006-08-02 CN disclosed
US-20060154173-A1 Resist composition SHOWA DENKO K.K. (JP) 2006-07-13 US disclosed
WO-2005047978-A1 AQUEOUS RESIST COMPOSITION SHOWA DENKO K.K. (JP) 2005-05-26 WO disclosed
US-20020058819-A1 METHOD OF PRODUCING 2,4-OXAZOLIDINEDIONES AND METAL SALTS THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED 2002-05-16 US disclosed
US-6384231-B1 CYCLIZATION OF 2 HYDROXYCARBOXYLATE WITH UREA; METAL ALKOXIDE; AROMATIC HYDROCARBON SOLVENT; BY-PRODUCT INHIBITION SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2002-05-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250009621-A1 ANHYDROUS HAIR TREATMENT COMPOSITION COMPRISING ALPHA HYDROXY ACID ESTER EBP, ADH1A, ADH1C HDAC1 3917/4885HDAC2 3189/4885HDAC3 3991/4885
US-20020058819-A1 METHOD OF PRODUCING 2,4-OXAZOLIDINEDIONES AND METAL SALTS THEREOF HAO2, AOC2, HAO1 HDAC1 1660/4885HDAC2 1049/4885HDAC3 2439/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.